AXGN Axogen
AxoGen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering . AxoGen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. AxoGen is part of the Sid Martin Biotechnology Incubator. As of 2019, AxoGen was the only commercially available allograft approved by the Food and Drug Administration for clinical use.[citation needed]
Company profile
Ticker
AXGN
Exchange
Website
CEO
Karen L. Zaderej
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Natus Medical • Masimo • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...
Former names
LECTEC CORP /MN/
SEC CIK
Corporate docs
IRS number
411301878
AXGN stock data
()
News
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
24 Feb 21
Stocks Making New 52-Week Highs/Lows For Tuesday, Feb. 23, 2021 (Via Benzinga Pro's Signals Tool)
23 Feb 21
Stocks That Hit 52-Week Highs On Tuesday
23 Feb 21
Canaccord Genuity Maintains Hold on Axogen, Raises Price Target to $21
23 Feb 21
10 Biggest Price Target Changes For Tuesday
23 Feb 21
Press releases
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
1 Mar 21
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
22 Feb 21
AxoGen, Inc. to Host Earnings Call
22 Feb 21
Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021
1 Feb 21
Investment data
Securities sold
Number of investors
Calendar
1 Mar 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Axogen earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 55.61M | 55.61M | 55.61M | 55.61M | 55.61M | 55.61M |
| Cash burn (monthly) | 4M | (positive/no burn) | 1.79M | 1.93M | (positive/no burn) | 802.17K |
| Cash used (since last report) | 14.26M | n/a | 6.38M | 6.89M | n/a | 2.86M |
| Cash remaining | 41.35M | n/a | 49.22M | 48.72M | n/a | 52.75M |
| Runway (months of cash) | 10.3 | n/a | 27.5 | 25.2 | n/a | 65.8 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Mar 21 | Zaderej Karen L. | Common Stock | Option exercise | Aquire M | No | No | 3.67 | 34,500 | 126.62K | 665,912 |
| 25 Mar 21 | Zaderej Karen L. | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.67 | 15,500 | 56.89K | 0 |
| 25 Mar 21 | Zaderej Karen L. | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.67 | 19,000 | 69.73K | 0 |
| 16 Mar 21 | Scopelianos Angelo | RSU Common Stock | Grant | Aquire A | No | No | 0 | 16,500 | 0 | 16,500 |
| 16 Mar 21 | Scopelianos Angelo | Employee Stock Option (right to purchase) Common Stock | Grant | Aquire A | No | No | 20.91 | 34,000 | 710.94K | 34,000 |
| 16 Mar 21 | Bradley Ottinger | RSU Common Stock | Grant | Aquire A | No | No | 0 | 7,690 | 0 | 19,490 |
| 16 Mar 21 | Bradley Ottinger | RSU Common Stock | Grant | Aquire A | No | No | 0 | 11,800 | 0 | 11,800 |
| 16 Mar 21 | Bradley Ottinger | Employee Stock Option (right to purchase) Common Stock | Grant | Aquire A | No | No | 20.91 | 23,500 | 491.39K | 23,500 |
| 16 Mar 21 | Sandberg Eric | RSU Common Stock | Grant | Aquire A | No | No | 0 | 11,800 | 0 | 11,800 |
| 16 Mar 21 | Sandberg Eric | Employee Stock Option (right to purchase) Common Stock | Grant | Aquire A | No | No | 20.91 | 23,500 | 491.39K | 23,500 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
97.7% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 122 |
| Opened positions | 20 |
| Closed positions | 18 |
| Increased positions | 38 |
| Reduced positions | 37 |
13F shares |
Current |
|---|---|
| Total value | 833.94M |
| Total shares | 39.82M |
| Total puts | 79K |
| Total calls | 94.1K |
| Total put/call ratio | 0.8 |
Largest owners |
Shares | Value |
|---|---|---|
| ArrowMark Colorado | 6.62M | $118.47M |
| Consonance Capital Management | 6.06M | $108.45M |
| BLK Blackrock | 3.01M | $53.81M |
| First Light Asset Management | 2.14M | $38.29M |
| Essex Woodlands Management | 1.98M | $35.48M |
| EW Healthcare Partners | 1.98M | $35.48M |
| Vanguard | 1.89M | $33.88M |
| JHG Janus Henderson | 1.51M | $26.94M |
| William Blair Investment Management | 1.35M | $24.2M |
| BAC Bank Of America | 1.24M | $22.26M |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abd, abroad, ACA, Accenture, Andersen, Argo, argument, ASSISTSM, Bach, background, Biden, bifurcated, bifurcation, BJ, border, Brendan, Britain, broader, Buckeye, camera, CECL, CEO, chain, claw, CLR, cold, commodity, competitor, complain, concurrently, consecutive, constantly, contra, correctly, covenant, COVID, currency, Cybercrime, cybersecurity, debate, deeper, deferral, Delinquent, demised, denominated, departure, depleting, deposit, deposited, Desai, Desirae, disburse, disbursed, DM, drove, DS, duration, echocardiography, enjoy, enterprise, escrow, Euro, exploit, family, FDARA, feature, feb, FJ, FKA, flat, foreclose, forty, fracture, Fraser, freestanding, freeze, GAAP, genomic, gift, GM, grace, Great, Greenberg, Harry, heard, heat, heightening, Hennepin, hernia, HIPAA, honesty, Horizon, host, hosted, Hoyen, HR, HSN, hybrid, idle, inaugural, inception, indemnified, insurrection, Intercontinental, IPO, IRR, issuable, ja, Jain, Jason, JF, JT, JV, Kao, landscape, language, layoff, Leversedge, Liberal, lifetime, lifted, Likewise, lived, LJ, MacKay, mandate, McKee, MedExec, Medwatch, Megee, MGT, MHRA, Michael, MicroPort, mid, Minn, MJ, NABP, nearby, necessitated, NeuraWrap, ninety, nuclear, nurse, Nydick, online, opposition, Ottinger, outbreak, overload, pandemic, partnership, pause, Paycheck, phishing, PhRMA, plain, PMID, PNA, possession, Pound, PPP, PRA, preceding, priority, Przylecki, punitive, PWERM, quickly, RANGERSM, realignment, reallocate, reallocated, reassessment, rebalanced, refocused, reinstated, renegotiated, repaid, rest, resume, resumed, revert, rollforward, RPA, RV, RWD, RWE, SA, SBA, scenario, Secretary, settlement, shoulder, slight, slowly, social, sophistication, spearheading, St, startup, stent, Styron, Subtopic, Supreme, Taiwan, temporarily, tenant, Tennessee, thoracic, threat, timeline, top, TPC, TR, transesophageal, Trump, unrest, upfront, Valerio, Vandelia, vanilla, virtual, war, WH, workforce, worth, WP
Removed:
Affordability, Alliance, alternate, Assay, BA, biomedical, biopharmaceutical, broaden, Chicago, comparability, compensatory, composed, contractor, coordination, credited, Decellularization, degrading, electrically, eleven, financed, founding, FreiMc, HTS, impossible, Italy, JD, Macalester, month, NeuraWrapTM, Obama, Occupancy, offsetting, outpaced, page, PDS, Pfizer, positioning, practiced, Quantech, quantitative, ran, recognizing, recording, rental, Selection, ship, sprouting, stacking, turnover, unchanged, unclear, USGAAP, Vermont, vitro, Wholesale, woman
Financial reports
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
30 Oct 20
10-Q
2020 Q2
Quarterly report
9 Aug 20
10-K/A
2019 FY
Annual report (amended)
12 Jun 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K/A
2018 FY
Annual report (amended)
30 Apr 19
Current reports
8-K
Entry into a Material Definitive Agreement
26 Feb 21
8-K
Axogen, Inc. Reports 2020 Fourth Quarter
22 Feb 21
8-K
Regulation FD Disclosure
18 Feb 21
8-K
Other Events
14 Jan 21
8-K
Axogen Reports Preliminary Unaudited Revenue
11 Jan 21
8-K
Departure of Directors or Certain Officers
6 Jan 21
8-K
Other Events
14 Dec 20
8-K
Entry into a Material Definitive Agreement
4 Dec 20
8-K
Axogen, Inc. Reports Third Quarter 2020 Financial Results
29 Oct 20
8-K
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
2 Oct 20
Registration and prospectus
424B3
Prospectus supplement
8 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Aug 19
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Aug 19
S-8
Registration of securities for employees
22 Aug 19
S-8
Registration of securities for employees
20 Mar 19
S-8
Registration of securities for employees
28 Aug 18
424B5
Prospectus supplement for primary offering
9 May 18
Proxies
DEF 14A
Definitive proxy
31 Mar 21
DEF 14A
Definitive proxy
17 Apr 20
DEF 14A
Definitive proxy
27 Jun 19
DEFA14A
Additional proxy soliciting materials
29 Mar 18
DEFA14A
Additional proxy soliciting materials
29 Mar 18
DEF 14A
Definitive proxy
28 Mar 18
PRE 14A
Preliminary proxy
14 Mar 18
DEF 14A
Definitive proxy
6 Apr 17
DEF 14A
Definitive proxy
7 Apr 16
DEF 14A
Definitive proxy
14 Apr 15
Other
UPLOAD
Letter from SEC
15 Jun 20
CORRESP
Correspondence with SEC
21 May 20
UPLOAD
Letter from SEC
26 Apr 20
CT ORDER
Confidential treatment order
5 Mar 19
CT ORDER
Confidential treatment order
29 Mar 18
EFFECT
Notice of effectiveness
10 Oct 17
CORRESP
Correspondence with SEC
5 Oct 17
UPLOAD
Letter from SEC
3 Oct 17
CT ORDER
Confidential treatment order
26 Mar 17
EFFECT
Notice of effectiveness
10 Dec 15
Ownership
4
Axogen / Karen L. Zaderej ownership change
29 Mar 21
4
Axogen / Mark Louis Friedman ownership change
18 Mar 21
4
Axogen / Isabelle Billet ownership change
18 Mar 21
4
Axogen / MARIA D. MARTINEZ ownership change
18 Mar 21
4
Axogen / Michael Patrick Donovan ownership change
18 Mar 21
4
Axogen / Erick Wayne DeVinney ownership change
18 Mar 21
4
Axogen / Karen L. Zaderej ownership change
18 Mar 21
4
Axogen / Bradley Ottinger ownership change
18 Mar 21
4
Axogen / Eric Sandberg ownership change
18 Mar 21
4
Axogen / PETER J MARIANI ownership change
18 Mar 21
Patents
GRANT
Utility
Materials and methods for protecting against neuromas
23 Mar 21
The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation.
APP
Utility
Tissue-processing Container for Automated Processing of Tissue, Methods of Use Thereof, and Systems Comprising the Same
18 Mar 21
Tissue-processing containers are disclosed for facilitating multistep processing of tissue.
GRANT
Utility
Implant devices with a pre-set pulley system
16 Mar 21
The problem of positioning one or more nerve ends inside a sheathing implant is solved by the use of a pulley and cinching systems that pull a nerve end into an implant and that can adjust the diameter of an implant to conform the implant to the diameter of the nerve, respectively.
GRANT
Utility
Materials and methods for protecting against neuromas
16 Mar 21
The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation.
APP
Utility
Connector and Wrap for End-to-side Nerve Coaptation
11 Mar 21
The problem of attaching a donor nerve stump to a recipient nerve for an end-to-side coaptation is solved by the use of a tissue connector.
Transcripts
2020 Q4
Earnings call transcript
23 Feb 21
2020 Q3
Earnings call transcript
1 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
8 May 20
2019 Q4
Earnings call transcript
24 Feb 20
2019 Q3
Earnings call transcript
6 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
8 May 19
2018 Q4
Earnings call transcript
26 Feb 19
2018 Q3
Earnings call transcript
29 Oct 18